Effects of White Rice, Brown Rice, and Black Rice on Postprandial Glucose and Lipid Profiles in Healthy Korean Adults
A Randomized, Crossover Clinical Trial
1 other identifier
interventional
15
1 country
1
Brief Summary
This study was an open, 5-treatment, 5-sequence, 5-day cross-over randomized design clinical trial. The present study was carried out to compare the effects of white rice, brown rice, and black rice on postprandial glucose and lipid profiles in healthy human subjects, using a white bread as a positive control.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable healthy
Started Mar 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 21, 2013
CompletedFirst Posted
Study publicly available on registry
August 30, 2013
CompletedSeptember 2, 2013
August 1, 2013
1 month
August 21, 2013
August 30, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
1. Glucose, insulin AUC(incremental area under the curve) 2. Glycemic index(GI)
1. Plasma glucose and insulin will be measured at baseline, 15, 30, 45, 60, 90, 120, 180 and 240 minutes post ingestion of each test solution, and area under the curve will be calculated. 2. Glycemic index (GI) was defined as the area under the glucose response curve after consumption of a test food divided by the area under the curve after consumption of a control food containing the same amount of carbohydrate and calculated using 50 g glucose as the reference. Plasma glucose will be measured at baseline, 15, 30, 45, 60, 90, and 120 minutes post ingestion of each test solution. GI= (incremental blood glucose area of test meal/incremental area of glucose) × 100
2 hour postprandial blood glucose, insulin
Secondary Outcomes (1)
Triglyceride iAUC(incremental area under the curve)
6 hour postprandial blood triglyceride(TG)
Other Outcomes (1)
Homeostatic model assessment-insulin resistance(HOMA-IR), quantitative insulin sensitivity check index(QUICKI), Insulinogenic index(IGI)
fasting and postprandial (different times for 30min)
Study Arms (5)
White rice
EXPERIMENTALBrown rice
EXPERIMENTALBlack rice
EXPERIMENTALBread
ACTIVE COMPARATORGlucose solution
ACTIVE COMPARATORInterventions
All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
Eligibility Criteria
You may qualify if:
- Males, 19\~60years old
- Bodyweight was more than 50 kg with ideal body weight within ±30%
- triglyceride (TG) levels less than 200 mg/dL
- Fasting blood glucose levels less than 100 mg/dL and an oral glucose tolerance test (OGTT) less than 140 mg/dL
- Able to give informed consent
You may not qualify if:
- Major medical illness such as cardiovascular, neurologic, psychiatric, renal, pulmonary and hepatic diseases
- History of disease that could interfere with the test products or impede their absorption such as gastrointestinal disease or gastrointestinal surgery
- Medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
- Poor vital sign (systolic blood pressure: below 100 mmHg or above 150 mmHg, diastolic blood pressure: below 65 mmHg or above95 mmHg)
- Allergic or hypersensitive to any of the ingredients in the test products; treated with any drug within past 2 weeks
- Participation in any other clinical trials within past 2 months
- Alcohol consumption above 21 units per week or abnormal screening laboratory test
- Being judged by the responsible physician of the local study center as unfit to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, 560-822, South Korea
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Soo-Wan Chae, MD., PhD
Chonbuk National University Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
August 21, 2013
First Posted
August 30, 2013
Study Start
March 1, 2011
Primary Completion
April 1, 2011
Study Completion
October 1, 2011
Last Updated
September 2, 2013
Record last verified: 2013-08